Cargando…

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma

We designed a phase I/II trial of S-1 combined with weekly docetaxel to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate the efficacy and toxicity in metastatic gastric carcinoma (MGC). Patients with measurable disease received S-1 orally b.i.d. on days 1–14 and d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, S R, Kim, H K, Kim, C G, Choi, I J, Lee, J S, Lee, J H, Ryu, K W, Kim, Y-W, Bae, J-M, Kim, N K
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361699/ https://www.ncbi.nlm.nih.gov/pubmed/18362939 http://dx.doi.org/10.1038/sj.bjc.6604312

Ejemplares similares

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group
por: Kim, J G, et al.
Publicado: (2008)

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
por: Yi, J H, et al.
Publicado: (2012)

A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer
por: Li, C-P, et al.
Publicado: (2010)

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer
por: Yamaguchi, K, et al.
Publicado: (2006)

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer
por: Takayama, T, et al.
Publicado: (2007)

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
por: Oh, S C, et al.
Publicado: (2005)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
por: Lee, J-L, et al.
Publicado: (2008)

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity
por: Kim, K-p, et al.
Publicado: (2011)

Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
por: Inokuchi, M, et al.
Publicado: (2006)

Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer
por: Jo, J-C, et al.
Publicado: (2012)

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer
por: Kang, H J, et al.
Publicado: (2008)

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
por: Han, S-W, et al.
Publicado: (2009)

A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer
por: Oh, S C, et al.
Publicado: (2007)

Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
por: Baek, J H, et al.
Publicado: (2006)

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study
por: Katsumata, N, et al.
Publicado: (2005)

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy
por: Kang, H J, et al.
Publicado: (2005)

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2004)

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer
por: Kim, S T, et al.
Publicado: (2005)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
por: Yoon, D H, et al.
Publicado: (2012)

Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial
por: Lorenzen, S, et al.
Publicado: (2005)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study
por: Awada, A, et al.
Publicado: (2008)

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
por: Roy, A, et al.
Publicado: (2012)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer
por: Dassen, Anneriet E, et al.
Publicado: (2016)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
por: Kang, Y-K, et al.
Publicado: (2013)

A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
por: Jeung, H-C, et al.
Publicado: (2007)

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011)

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer
por: Atmaca, A, et al.
Publicado: (2013)

Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
por: Engebraaten, Olav, et al.
Publicado: (2012)

Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer
por: Lordick, F, et al.
Publicado: (2005)

A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2006)

Phase II trial of imatinib mesylate in patients with metastatic melanoma
por: Kim, K B, et al.
Publicado: (2008)

Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks
por: Nomiya, T, et al.
Publicado: (2014)

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
por: Gamucci, T, et al.
Publicado: (2007)

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
por: Ciardiello, F, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_j48dnkg3q92n33j6438ef4e7l0